# Myriad Genetics Inc: overview

MYGN · Nasdaq · CIK 899923 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mygn.md) · [Financials](/companies/mygn/financials.md) · [Filings](/companies/mygn/filings.md) · [Insiders](/companies/mygn/insiders.md)

Latest reported revenue: [$190.7m](/filings/0000899923-26-000072.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000899923-26-000072).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [213](/filings/0000899923-25-000112.md) | [211 d](/filings/0000899923-26-000018.md) | [196](/filings/0000899923-26-000038.md) | [213](/filings/0000899923-26-000072.md) | [206](/filings/0000899923-25-000112.md) | [210 d](/filings/0000899923-26-000018.md) | [200](/filings/0000899923-26-000038.md) | [191](/filings/0000899923-26-000072.md) |
| Gross margin | % | [70.2%](/filings/0000899923-25-000112.md) | [71.7% d](/filings/0000899923-26-000018.md) | [68.5%](/filings/0000899923-26-000038.md) | [71.2%](/filings/0000899923-26-000072.md) | [69.9%](/filings/0000899923-25-000112.md) | [70.0% d](/filings/0000899923-26-000018.md) | [68.7%](/filings/0000899923-26-000038.md) | [66.6%](/filings/0000899923-26-000072.md) |
| Operating margin | % | [(9.4%)](/filings/0000899923-25-000112.md) | [(18.5%) d](/filings/0000899923-26-000018.md) | [(14.8%)](/filings/0000899923-26-000038.md) | [(154.5%)](/filings/0000899923-26-000072.md) | [(11.3%)](/filings/0000899923-25-000112.md) | [(2.7%) d](/filings/0000899923-26-000018.md) | [(15.3%)](/filings/0000899923-26-000038.md) | [(20.4%)](/filings/0000899923-26-000072.md) |
| Net margin | % | [(10.4%)](/filings/0000899923-25-000112.md) | [(20.2%) d](/filings/0000899923-26-000018.md) | [(0.1%)](/filings/0000899923-26-000072.md) | [(155.1%)](/filings/0000899923-26-000072.md) | [(13.3%)](/filings/0000899923-25-000112.md) | [(3.8%) d](/filings/0000899923-26-000018.md) | [(17.0%)](/filings/0000899923-26-000072.md) | [(22.7%)](/filings/0000899923-26-000072.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0000899923-25-000112.md) | not reported | [0.00](/filings/0000899923-26-000038.md) | [(3.57)](/filings/0000899923-26-000072.md) | [(0.29)](/filings/0000899923-25-000112.md) | not reported | [(0.36)](/filings/0000899923-26-000038.md) | [(0.46)](/filings/0000899923-26-000072.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [691](/filings/0000899923-24-000018.md) | [678](/filings/0000899923-25-000019.md) | [753](/filings/0000899923-26-000018.md) | [838](/filings/0000899923-26-000018.md) | [825](/filings/0000899923-26-000018.md) |
| Gross margin | % | not reported | [70.2%](/filings/0000899923-25-000019.md) | [68.6%](/filings/0000899923-26-000018.md) | [69.9%](/filings/0000899923-26-000018.md) | [69.9%](/filings/0000899923-26-000018.md) |
| Operating margin | % | [(27.6%)](/filings/0000899923-24-000018.md) | [(20.7%)](/filings/0000899923-25-000019.md) | [(34.2%)](/filings/0000899923-26-000018.md) | [(14.7%)](/filings/0000899923-26-000018.md) | [(47.0%)](/filings/0000899923-26-000018.md) |
| Net margin | % | [(3.9%)](/filings/0000899923-24-000018.md) | [(16.5%)](/filings/0000899923-25-000019.md) | [(35.0%)](/filings/0000899923-26-000018.md) | [(15.2%)](/filings/0000899923-26-000018.md) | [(44.4%)](/filings/0000899923-26-000018.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0000899923-24-000018.md) | [(1.39)](/filings/0000899923-25-000019.md) | [(3.18)](/filings/0000899923-26-000018.md) | [(1.41)](/filings/0000899923-26-000018.md) | [(3.95)](/filings/0000899923-26-000018.md) |
| Free cash flow | $m | [0.6](/filings/0000899923-24-000018.md) | [(152)](/filings/0000899923-25-000019.md) | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mygn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $62.2m | 10,890,440 |  | Added +2,000,796 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $37.8m | 6,620,372 |  | Reduced −48,445 |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $32.7m | 5,735,000 |  | Added +4,087,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $28.5m | 4,985,060 |  | Added +561,033 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $26.2m | 4,582,083 |  | Added +82,359 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $23.3m | 4,081,376 |  | Added +156,851 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $17.6m | 3,079,670 |  | Added +497,439 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $15.8m | 2,766,689 |  | Added +854,393 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $14.2m | 2,481,104 |  | Reduced −687,638 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.8m | 2,416,197 |  | Added +96,818 |

## Recent filings

[All 1,466 filings](/companies/mygn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 08:36 ET | [8-K](/filings/0000899923-26-000094.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000899923-26-000094 |
| 2026-10-09 | 16:16 ET | [8-K](/filings/0000899923-26-000084.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000899923-26-000084 |
| 2026-09-16 | 08:00 ET | [8-K](/filings/0000899923-26-000079.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000899923-26-000079 |
| 2026-07-31 | 08:01 ET | [10-Q](/filings/0000899923-26-000072.md) | Quarterly report, period 2026-06-30 | 0000899923-26-000072 |
| 2026-07-30 | 16:07 ET | [8-K](/filings/0000899923-26-000070.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000899923-26-000070 |
| 2026-06-23 | 08:32 ET | [8-K](/filings/0000899923-26-000062.md) | 5.02 Departure or appointment of officers or directors | 0000899923-26-000062 |
| 2026-06-04 | 16:08 ET | [8-K](/filings/0000899923-26-000059.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000899923-26-000059 |
| 2026-05-06 | 06:05 ET | [10-Q](/filings/0000899923-26-000038.md) | Quarterly report, period 2026-03-31 | 0000899923-26-000038 |
| 2026-05-05 | 16:07 ET | [8-K](/filings/0000899923-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000899923-26-000036 |
| 2026-04-14 | 17:01 ET | [DEF 14A](/filings/0000899923-26-000031.md) | Proxy statement, period 2025-12-31 | 0000899923-26-000031 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000899923-26-000018.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bde940dc-8a13-4006-bd16-487dccbea03c)

## About the filer

- CIK: 899923
- Tickers: MYGN
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:12 ET. No prices; not investment advice.